Table 4

Hypertension and/or diabetes, and CKD status.

Clinical features

CKD patients

Non CKD patients

Total

P


JNC 7 guidelines

All patients (BP in mmHg)

Normal, < 120 and < 80

52 (27.5)

143 (43.2)

195 (35.5)

0.0005

PreHBP, 120–139 or 80–89

32 (16.9)

56 (19.6)

88 (16.9)

0.5

Stage 1, 140–159 or 90–99

38 (20.1)

72 (21.8)

110 (21.2)

0.7

Stage 2, ≥ 160 or ≥ 100

67 (35.4)

60 (18.1)

127 (24.4)

<0.0001

Hypertensives

Antihypertensive drugs

none

1 (1.1)

11 (10.6)

22 (11.2)

0.01

Any treatment

89 (98.9)

93 (89.4)

182 (88.8)

0.01

1 antihypertensive

62 (71.3)

60 (57.7)

122 (62.2)

0.06

mean antihypertensive drugs

1.28 ± 0.5

1.22 ± 0.6

1.25 ± 0.6

0.1

ACEI*

21 (23.3)

33 (31.7)

54 (27.7)

0.2

Normal, < 120 and < 80

7 (5.2)

17 (10.0)

24 (7.9)

0.1

High normal, 120–139 or 80–89

22 (16.4)

21 (12.4)

43 (14.1)

0.4

Stage 1, 140–159 or 90–99

38 (28.4)

72 (42.4)

110 (36.2)

0.01

Stage 2, ≥ 160 or ≥ 110

67 (50.0)

60 (35.3)

127 (41.8)

0.01

< 130/80

8 (6.0)

21 (12.4)

29 (9.5)

0.09

< 125/75

4 (3.0)

11 (6.5)

15 (4.9)

0.2

Serum glucose level (mg/dl)

Diabetics

< 110

14 (12.8)

17 (9.8)

31 (11.0)

0.5

110–125

8 (7.3)

12 (6.9)

20 (7.1)

0.9

≥ 126

87 (79.8)

145 (83.3)

232 (82.0)

0.5

≥ 180

45 (41.3)

91 (52.3)

136 (48.1)

0.09


Values expressed as numbers and proportions in parentheses or mean ± SD, as appropriate.

CKD is defined either kidney damage (proteinuria ≥ 300 mg/day) and/or kidney function (< 60 ml/min/1.73 m2).

Percentages based on responding number, not total participant number.

ACEI: Angiotensin-Converting Enzyme Inhibitors. PreHTN = Prehypertension.

Sumaili et al. BMC Nephrology 2009 10:18   doi:10.1186/1471-2369-10-18

Open Data